Here is the synopsis of our sample research paper on Merck, Pfizer And Johnson & Johnson: Marketing Amidst Problem Products. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
10 pages in length. The writer discusses the problems each company may face when reintroducing their respective products – Vioxx, Celebrex – to the market if FDA approval is received. Bibliography lists 7 sources.
Page Count:
10 pages (~225 words per page)
File: LM1_TLCMerckPfz.rtf
Buy This Term Paper »
Unformatted sample text from the term paper:
whose focus is on its profit margin rather than its social responsibility. The companys strategy/tactics for reintroducing Vioxx if/when the FDA permits it back on the market must reflect
Mercks suspected knowledge of the drugs serious side effects long before it was pulled from the market. If it comes to pass that Merck had prior knowledge of this
significant heart risk, one might readily surmise how any amount or type of advertising campaign will fail to undo the damage such massive deceit has caused. Based upon the wholly
incriminating "internal Merck e-mails and marketing materials as well as interviews with outside scientists" (Mathews et al, 2004, p. A1), the companys credibility for, according to Chief Executive Raymond Gilmartin,
"putting patient safety first" (p. A1) has been tainted beyond repair, no matter how carefully or responsibly Merck might approach its products re-entry into the market. One might readily
surmise how only a handful of consumers who have limited options will take the risks inherent to Vioxx, leaving the vast majority to stand firm against financially supporting a company
that, if proven, knew all along the serious side effects of its tremendous moneymaking drug. "The revelations shed new light on the interplay between marketing and science at Merck
as bad news piled up about a blockbuster drug used by some 20 million Americans. Amid growing danger signs, Merck fought a rearguard action for 4 1/2 years, clinging
to a hope that somehow Vioxxs safety could be confirmed -- even though its research chief had already privately acknowledged its risks" (Mathews et al, 2004, p. A1).
According to Alastair Wood, chairman of the FDAs advisory panel and a professor at Vanderbilt University, "many on the committee, including myself, were trying
...